Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKS-130
- Development stage
- Discontinued
- Lead developer
- Akston Biosciences
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Intraperitoneal, Parenteral, Subcutaneous
01
Overview
AKS-130 is a novel insulin-Fc fusion protein developed by Akston Biosciences. It was designed as a long-acting insulin analog that acts as a modest agonist of the insulin receptor (IR). AKS-130 lowers blood glucose levels without causing clinical hypoglycemia, and it has been investigated for its potential to target and downregulate insulin receptors in cancer cells. Preclinical studies have demonstrated that AKS-130 downregulates IR expression and partially blocks downstream PI3K/Akt signaling, suppressing tumor growth in xenograft models of colorectal cancer, malignant melanoma, and estrogen receptor-positive (ER+) breast cancer.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on AKS-130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKS-130.